Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease

Respirology

Volumn 23, Issue 5, 2018, Pages 455-466

  Goletti, Delia ^a   Lee, Meng Rui ^b   Wang, Jann Yuan ^b   Walter, Nicholas ^c   Ottenhoff, Tom H M ^d  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c Department of Civil and Environmental Engineering at Colorado State University and the Department of Environmental and Occupational Health at the Colorado School of Public Health   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

active disease; biomarkers; cure; incipient tuberculosis; latent infection

Indexed keywords

BACTERIAL DNA; BIOLOGICAL MARKER; FIBRINOGEN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 23; KI 67 ANTIGEN; SCLEROPROTEIN; SCLEROPROTEIN 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VOLATILE ORGANIC COMPOUND; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; BCG VACCINE; PROTEOME; TRANSCRIPTOME;

BACTERIAL LOAD; BLOOD ANALYSIS; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CORRELATIONAL STUDY; DISEASE COURSE; GENOME ANALYSIS; HOST PATHOGEN INTERACTION; HUMAN; INTERFERON GAMMA RELEASE ASSAY; MYCOBACTERIUM TUBERCULOSIS; PATHOGENESIS; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; RNA SEQUENCE; SALIVA ANALYSIS; SENSITIVITY AND SPECIFICITY; SEROLOGY; SPUTUM ANALYSIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSCRIPTOMICS; TREATMENT RESPONSE; TUBERCULIN TEST; TUBERCULOSIS; URINALYSIS; BLOOD; IMMUNOLOGY; LATENT TUBERCULOSIS; METABOLOME; RISK ASSESSMENT; URINE;

ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BIOMARKERS; DNA, BACTERIAL; HUMANS; LATENT TUBERCULOSIS; METABOLOME; MYCOBACTERIUM TUBERCULOSIS; PROTEOME; RISK ASSESSMENT; TRANSCRIPTOME; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 85042064378     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.13272     Document Type: Review

References (120)

1. WHO. Tuberculosis fact sheet, 2017. Available from URL: http://www.who.int/mediacentre/factsheets/fs104/en/
2. Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016; 13: e1002152.
3. Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection-associated tuberculosis: the epidemiology and the response. Clin. Infect. Dis. 2010; 50(Suppl. 3): S201–7.
4. Cantini F, Goletti D. Biologics and tuberculosis risk: the rise and fall of an old disease and its new resurgence. J. Rheumatol. Suppl. 2014; 91: 1–3.
5. Girardi E, Sane Schepisi M, Goletti D, Bates M, Mwaba P, Yeboah-Manu D, Ntoumi F, Palmieri F, Maeurer M, Zumla A et al. The global dynamics of diabetes and tuberculosis: the impact of migration and policy implications. Int. J. Infect. Dis. 2017; 56: 45–53.
6. Zellweger JP, Sotgiu G, Block M, Dore S, Altet N, Blunschi R, Bogyi M, Bothamley G, Bothe C, Codecasa L et al.; TBNET. Risk assessment of tuberculosis in contacts by IFN-gamma release assays. A Tuberculosis Network European Trials Group Study. Am. J. Respir. Crit. Care Med. 2015; 191: 1176–84.
7. Lagrange PH, Thangaraj SK, Dayal R, Despande A, Ganguly NK, Girardi E, Joshi B, Katoch K, Katoch VM, Kumar M et al. A toolbox for tuberculosis diagnosis: an Indian multicentric study (2006-2008): microbiological results. PLoS One 2012; 7: e43739.
8. Davies PD, Pai M. The diagnosis and misdiagnosis of tuberculosis. Int. J. Tuberc. Lung Dis. 2008; 12: 1226–34.
9. WHO. High-priority target product profiles for new tuberculosis diagnostics. Report of a consensus meeting, 2014. Available from URL: http://www.who.int/tb/publications/tpp_report/en/
10. Denkinger CM, Kik SV, Cirillo DM, Casenghi M, Shinnick T, Weyer K, Gilpin C, Boehme CC, Schito M, Kimerling M et al. Defining the needs for next generation assays for tuberculosis. J. Infect. Dis. 2015; 211(Suppl. 2): S29–38.
11. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001; 69: 89–95.
12. Etheridge A, Lee I, Hood L, Galas D, Wang K. Extracellular microRNA: a new source of biomarkers. Mutat. Res. 2011; 717: 85–90.
13. Nalejska E, Maczynska E, Lewandowska MA. Prognostic and predictive biomarkers: tools in personalized oncology. Mol. Diagn. Ther. 2014; 18: 273–84.
14. Buschmann D, Haberberger A, Kirchner B, Spornraft M, Riedmaier I, Schelling G, Pfaffl MW. Toward reliable biomarker signatures in the age of liquid biopsies - how to standardize the small RNA-Seq workflow. Nucleic Acids Res. 2016; 44: 5995–6018.
15. Ballman KV. Biomarker: predictive or prognostic? J. Clin. Oncol. 2015; 33: 3968–71.
16. Strimbu K, Tavel JA. What are biomarkers? Curr. Opin. HIV AIDS 2010; 5: 463–6.
17. Southern TR, Racsa LD, Albarino CG, Fey PD, Hinrichs SH, Murphy CN, Herrera VL, Sambol AR, Hill CE, Ryan EL et al. Comparison of FilmArray and quantitative real-time reverse transcriptase PCR for detection of Zaire ebolavirus from contrived and clinical specimens. J. Clin. Microbiol. 2015; 53: 2956–60.
18. van der Zee A, Roorda L, Bosman G, Ossewaarde JM. Molecular diagnosis of urinary tract infections by semi-quantitative detection of uropathogens in a routine clinical hospital setting. PLoS One 2016; 11: e0150755.
19. Andries AC, Duong V, Ly S, Cappelle J, Kim KS, Lorn Try P, Ros S, Ong S, Huy R, Horwood P et al. Value of routine dengue diagnostic tests in urine and saliva specimens. PLoS Negl. Trop. Dis. 2015; 9: e0004100.
20. Green C, Huggett JF, Talbot E, Mwaba P, Reither K, Zumla AI. Rapid diagnosis of tuberculosis through the detection of mycobacterial DNA in urine by nucleic acid amplification methods. Lancet Infect. Dis. 2009; 9: 505–11.
21. Iwasaki H, Chagan-Yasutan H, Leano PS, Koizumi N, Nakajima C, Taurustiati D, Hanan F, Lacuesta TL, Ashino Y, Suzuki Y et al. Combined antibody and DNA detection for early diagnosis of leptospirosis after a disaster. Diagn. Microbiol. Infect. Dis. 2016; 84: 287–91.
22. Cannas A, Calvo L, Chiacchio T, Cuzzi G, Vanini V, Lauria FN, Pucci L, Girardi E, Goletti D. IP-10 detection in urine is associated with lung diseases. BMC Infect. Dis. 2010; 10: 333.
23. Kerkhoff AD, Barr DA, Schutz C, Burton R, Nicol MP, Lawn SD, Meintjes G. Disseminated tuberculosis among hospitalised HIV patients in South Africa: a common condition that can be rapidly diagnosed using urine-based assays. Sci. Rep. 2017; 7: 10931.
24. Lawn SD, Kerkhoff AD, Burton R, Schutz C, Boulle A, Vogt M, Gupta-Wright A, Nicol MP, Meintjes G. Diagnostic accuracy, incremental yield and prognostic value of Determine TB-LAM for routine diagnostic testing for tuberculosis in HIV-infected patients requiring acute hospital admission in South Africa: a prospective cohort. BMC Med. 2017; 15: 67.
25. Minion J, Leung E, Talbot E, Dheda K, Pai M, Menzies D. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. Eur. Respir. J. 2011; 38: 1398–405.
26. Kashyap RS, Rajan AN, Ramteke SS, Agrawal VS, Kelkar SS, Purohit HJ, Taori GM, Daginawala HF. Diagnosis of tuberculosis in an Indian population by an indirect ELISA protocol based on detection of antigen 85 complex: a prospective cohort study. BMC Infect. Dis. 2007; 7: 74.
27. Bentley-Hibbert SI, Quan X, Newman T, Huygen K, Godfrey HP. Pathophysiology of antigen 85 in patients with active tuberculosis: antigen 85 circulates as complexes with fibronectin and immunoglobulin G. Infect. Immun. 1999; 67: 581–8.
28. Liu C, Zhao Z, Fan J, Lyon CJ, Wu HJ, Nedelkov D, Zelazny AM, Olivier KN, Cazares LH, Holland SM et al. Quantification of circulating Mycobacterium tuberculosis antigen peptides allows rapid diagnosis of active disease and treatment monitoring. Proc. Natl. Acad. Sci. U. S. A. 2017; 114: 3969–74.
29. Young BL, Mlamla Z, Gqamana PP, Smit S, Roberts T, Peter J, Theron G, Govender U, Dheda K, Blackburn J. The identification of tuberculosis biomarkers in human urine samples. Eur. Respir. J. 2014; 43: 1719–29.
30. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, Wilkinson KA, Banchereau R, Skinner J, Wilkinson RJ et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466: 973–7.
31. Anderson ST, Kaforou M, Brent AJ, Wright VJ, Banwell CM, Chagaluka G, Crampin AC, Dockrell HM, French N, Hamilton MS et al.; ILULU Consortium; KIDS TB Study Group. Diagnosis of childhood tuberculosis and host RNA expression in Africa. N. Engl. J. Med. 2014; 370: 1712–23.
32. Bloom CI, Graham CM, Berry MP, Rozakeas F, Redford PS, Wang Y, Xu Z, Wilkinson KA, Wilkinson RJ, Kendrick Y et al. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS One 2013; 8: e70630.
33. Kaforou M, Wright VJ, Oni T, French N, Anderson ST, Bangani N, Banwell CM, Brent AJ, Crampin AC, Dockrell HM et al. Detection of tuberculosis in HIV-infected and -uninfected African adults using whole blood RNA expression signatures: a case-control study. PLoS Med. 2013; 10: e1001538.
34. Ottenhoff TH. New pathways of protective and pathological host defense to mycobacteria. Trends Microbiol. 2012; 20: 419–28.
35. Ottenhoff TH. The knowns and unknowns of the immunopathogenesis of tuberculosis. Int. J. Tuberc. Lung Dis. 2012; 16: 1424–32.
36. Ottenhoff TH, Ellner JJ, Kaufmann SH. Ten challenges for TB biomarkers. Tuberculosis (Edinb.) 2012; 92(Suppl. 1): S17–20.
37. Sweeney TE, Braviak L, Tato CM, Khatri P. Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis. Lancet Respir. Med. 2016; 4: 213–24.
38. Maertzdorf J, Repsilber D, Parida SK, Stanley K, Roberts T, Black G, Walzl G, Kaufmann SH. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun. 2011; 12: 15–22.
39. Weiner J 3rd, Parida SK, Maertzdorf J, Black GF, Repsilber D, Telaar A, Mohney RP, Arndt-Sullivan C, Ganoza CA, Fae KC et al. Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS One 2012; 7: e40221.
40. Chegou NN, Sutherland JS, Malherbe S, Crampin AC, Corstjens PL, Geluk A, Mayanja-Kizza H, Loxton AG, van der Spuy G, Stanley K et al.; AE-TBC Consortium. Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB. Thorax 2016; 71: 785–94.
41. Corstjens PL, Tjon Kon Fat EM, de Dood CJ, van der Ploeg-van Schip JJ, Franken KL, Chegou NN, Sutherland JS, Howe R, Mihret A, Kassa D et al.; AE-TBC Consortium. Multi-center evaluation of a user-friendly lateral flow assay to determine IP-10 and CCL4 levels in blood of TB and non-TB cases in Africa.Clin. Biochem. 2016; 49: 22–31.
42. Esmail H, Lai RP, Lesosky M, Wilkinson KA, Graham CM, Coussens AK, Oni T, Warwick JM, Said-Hartley Q, Koegelenberg CF et al. Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[18F]fluoro-D-glucose positron emission and computed tomography. Nat. Med. 2016; 22: 1090–3.
43. Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M, Tanner R, O'Shea MK, Dheenadhayalan V et al. T-cell activation is an immune correlate of risk in BCG vaccinated infants. Nat. Commun. 2016; 7: 11290.
44. Chegou NN, Detjen AK, Thiart L, Walters E, Mandalakas AM, Hesseling AC, Walzl G. Utility of host markers detected in Quantiferon supernatants for the diagnosis of tuberculosis in children in a high-burden setting. PLoS One 2013; 8: e64226.
45. Azzurri A, Sow OY, Amedei A, Bah B, Diallo S, Peri G, Benagiano M, D'Elios MM, Mantovani A, Del Prete G. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect. 2005; 7: 1–8.
46. Geluk A, van Meijgaarden KE, Wilson L, Bobosha K, van der Ploeg-van Schip JJ, van den Eeden SJ, Quinten E, Dijkman K, Franken KL, Haisma EM et al. Longitudinal immune responses and gene expression profiles in type 1 leprosy reactions. J. Clin. Immunol. 2014; 34: 245–55.
47. Bobosha K, Tjon Kon Fat EM, van den Eeden SJ, Bekele Y, van der Ploeg-van Schip JJ, de Dood CJ, Dijkman K, Franken KL, Wilson L, Aseffa A et al. Field-evaluation of a new lateral flow assay for detection of cellular and humoral immunity against Mycobacterium leprae. PLoS Negl. Trop. Dis. 2014; 8: e2845.
48. Whittaker E, Gordon A, Kampmann B. Is IP-10 a better biomarker for active and latent tuberculosis in children than IFNgamma? PLoS One 2008; 3: e3901.
49. Petrone L, Cannas A, Aloi F, Nsubuga M, Sserumkuma J, Nazziwa RA, Jugheli L, Lukindo T, Girardi E, Reither K et al. Blood or urine IP-10 cannot discriminate between active tuberculosis and respiratory diseases different from tuberculosis in children. Biomed. Res. Int. 2015; 2015: 589471.
50. Petrone L, Vanini V, Petruccioli E, Ettorre GM, Schinina V, Busi Rizzi E, Ludovisi A, Corpolongo A, Ippolito G, Pozio E et al. Polyfunctional specific response to Echinococcus granulosus associates to the biological activity of the cysts. PLoS Negl. Trop. Dis. 2015; 9: e0004209.
51. Petrone L, Chiacchio T, Vanini V, Petruccioli E, Cuzzi G, Di Giacomo C, Pucci L, Montalbano M, Lionetti R, Testa A et al. High urine IP-10 levels associate with chronic HCV infection. J. Infect. 2014; 68: 591–600.
52. Petrone L, Cannas A, Vanini V, Cuzzi G, Aloi F, Nsubuga M, Sserunkuma J, Nazziwa RA, Jugheli L, Lukindo T et al. Blood and urine inducible protein 10 as potential markers of disease activity. Int. J. Tuberc. Lung Dis. 2016; 20: 1554–61.
53. Oved K, Cohen A, Boico O, Navon R, Friedman T, Etshtein L, Kriger O, Bamberger E, Fonar Y, Yacobov R et al. A novel host-proteome signature for distinguishing between acute bacterial and viral infections. PLoS One 2015; 10: e0120012.
54. Jacobs R, Maasdorp E, Malherbe S, Loxton AG, Stanley K, van der Spuy G, Walzl G, Chegou NN. Diagnostic potential of novel salivary host biomarkers as candidates for the immunological diagnosis of tuberculosis disease and monitoring of tuberculosis treatment response. PLoS One 2016; 11: e0160546.
55. Phalane KG, Kriel M, Loxton AG, Menezes A, Stanley K, van der Spuy GD, Walzl G, Chegou NN. Differential expression of host biomarkers in saliva and serum samples from individuals with suspected pulmonary tuberculosis. Mediators Inflamm. 2013; 2013: 981984.
56. Duvall MG, Precopio ML, Ambrozak DA, Jaye A, McMichael AJ, Whittle HC, Roederer M, Rowland-Jones SL, Koup RA. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur. J. Immunol. 2008; 38: 350–63.
57. Caccamo N, Guggino G, Joosten SA, Gelsomino G, Di Carlo P, Titone L, Galati D, Bocchino M, Matarese A, Salerno A et al. Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. Eur. J. Immunol. 2010; 40: 2211–20.
58. Petruccioli E, Petrone L, Vanini V, Sampaolesi A, Gualano G, Girardi E, Palmieri F, Goletti D. IFNgamma/TNFalpha specific-cells and effector memory phenotype associate with active tuberculosis. J. Infect. 2013; 66: 475–86.
59. Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, Pinnetti C, Sampaolesi A, Antinori A, Girardi E, Goletti D. Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients. J. Infect. 2014; 69: 533–45.
60. Harari A, Rozot V, Bellutti Enders F, Perreau M, Stalder JM, Nicod LP, Cavassini M, Calandra T, Blanchet CL, Jaton K et al. Dominant TNF-alpha+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat. Med. 2011; 17: 372–6.
61. Pollock KM, Whitworth HS, Montamat-Sicotte DJ, Grass L, Cooke GS, Kapembwa MS, Kon OM, Sampson RD, Taylor GP, Lalvani A. T-cell immunophenotyping distinguishes active from latent tuberculosis. J. Infect. Dis. 2013; 208: 952–68.
62. Goletti D, Butera O, Bizzoni F, Casetti R, Girardi E, Poccia F. Region of difference 1 antigen-specific CD4+ memory T cells correlate with a favorable outcome of tuberculosis. J. Infect. Dis. 2006; 194: 984–92.
63. Petruccioli E, Petrone L, Vanini V, Cuzzi G, Navarra A, Gualano G, Palmieri F, Girardi E, Goletti D. Assessment of CD27 expression as a tool for active and latent tuberculosis diagnosis. J. Infect. 2015; 71: 526–33.
64. Portevin D, Moukambi F, Clowes P, Bauer A, Chachage M, Ntinginya NE, Mfinanga E, Said K, Haraka F, Rachow A et al. Assessment of the novel T-cell activation marker-tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study. Lancet Infect. Dis. 2014; 14: 931–8.
65. Nikitina IY, Kondratuk NA, Kosmiadi GA, Amansahedov RB, Vasilyeva IA, Ganusov VV, Lyadova IV. Mtb-specific CD27low CD4 T cells as markers of lung tissue destruction during pulmonary tuberculosis in humans. PLoS One 2012; 7: e43733.
66. Adekambi T, Ibegbu CC, Cagle S, Kalokhe AS, Wang YF, Hu Y, Day CL, Ray SM, Rengarajan J. Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response. J. Clin. Invest. 2015; 125: 1827–38.
67. Rozot V, Vigano S, Mazza-Stalder J, Idrizi E, Day CL, Perreau M, Lazor-Blanchet C, Petruccioli E, Hanekom W, Goletti D et al. Mycobacterium tuberculosis-specific CD8 T cells are functionally and phenotypically different between latent infection and active disease. Eur. J. Immunol. 2013; 43: 1568–77.
68. Rozot V, Patrizia A, Vigano S, Mazza-Stalder J, Idrizi E, Day CL, Perreau M, Lazor-Blanchet C, Ohmiti K, Goletti D et al. Combined use of Mycobacterium tuberculosis-specific CD4 and CD8 T-cell responses is a powerful diagnostic tool of active tuberculosis. Clin. Infect. Dis. 2015; 60: 432–7.
69. Naranbhai V, Fletcher HA, Tanner R, O'Shea MK, McShane H, Fairfax BP, Knight JC, Hill AV. Distinct transcriptional and anti-mycobacterial profiles of peripheral blood monocytes dependent on the ratio of monocytes: lymphocytes. EBioMedicine 2015; 2: 1619–26.
70. Naranbhai V, Hill AV, Abdool Karim SS, Naidoo K, Abdool Karim Q, Warimwe GM, McShane H, Fletcher H. Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy. J. Infect. Dis. 2014; 209: 500–9.
71. Naranbhai V, Moodley D, Chipato T, Stranix-Chibanda L, Nakabaiito C, Kamateeka M, Musoke P, Manji K, George K, Emel LM et al.; HPTN 046 Protocol Team. The association between the ratio of monocytes: lymphocytes and risk of tuberculosis among HIV-infected postpartum women. J. Acquir. Immune Defic. Syndr. 2014; 67: 573–5.
72. La Manna MP, Orlando V, Dieli F, Di Carlo P, Cascio A, Cuzzi G, Palmieri F, Goletti D, Caccamo N. Quantitative and qualitative profiles of circulating monocytes may help identifying tuberculosis infection and disease stages. PLoS One 2017; 12: e0171358.
73. WHO. Commercial serodiagnostic tests for diagnosis of tuberculosis: policy statement. WHO Library Cataloguing-in-Publication Data, 2011. Available from URL: http://www.tbcindia.nic.in/pdfs/WHO_Policy_Serology_2011.pdf
74. Steingart KR, Flores LL, Dendukuri N, Schiller I, Laal S, Ramsay A, Hopewell PC, Pai M. Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis. PLoS Med. 2011; 8: e1001062.
75. Jones A, Pitts M, Al Dulayymi JR, Gibbons J, Ramsay A, Goletti D, Gwenin CD, Baird MS. New synthetic lipid antigens for rapid serological diagnosis of tuberculosis. PLoS One 2017; 12: e0181414.
76. Khaliq A, Ravindran R, Hussainy SF, Krishnan VV, Ambreen A, Yusuf NW, Irum S, Rashid A, Jamil M, Zaffar F et al. Field evaluation of a blood based test for active tuberculosis in endemic settings. PLoS One 2017; 12: e0173359.
77. Agranoff D, Fernandez-Reyes D, Papadopoulos MC, Rojas SA, Herbster M, Loosemore A, Tarelli E, Sheldon J, Schwenk A, Pollok R et al. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 2006; 368: 1012–21.
78. Phillips M, Basa-Dalay V, Bothamley G, Cataneo RN, Lam PK, Natividad MP, Schmitt P, Wai J. Breath biomarkers of active pulmonary tuberculosis. Tuberculosis (Edinb.) 2010; 90: 145–51.
79. Teixeira RC, Rodríguez M, Jiménez de Romero N, Bruins M, Gómez R, Yntema JB, Chaparro Abente G, Gerritsen JW, Wiegerinck W, Pérez Bejerano D et al. The potential of a portable, point-of-care electronic nose to diagnose tuberculosis. J. Infect. 2017; 75: 441–7.
80. Zetola NM, Modongo C, Matsiri O, Tamuhla T, Mbongwe B, Matlhagela K, Sepako E, Catini A, Sirugo G, Martinelli E et al. Diagnosis of pulmonary tuberculosis and assessment of treatment response through analyses of volatile compound patterns in exhaled breath samples. J. Infect. 2017; 74: 367–76.
81. Barry CE 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 2009; 7: 845–55.
82. Cadena AM, Fortune SM, Flynn JL. Heterogeneity in tuberculosis. Nat. Rev. Immunol. 2017; 17: 691–702.
83. Dorhoi A, Kaufmann SH. Pathology and immune reactivity: understanding multidimensionality in pulmonary tuberculosis. Semin. Immunopathol. 2016; 38: 153–66.
84. Delogu G, Goletti D. The spectrum of tuberculosis infection: new perspectives in the era of biologics. J. Rheumatol. Suppl. 2014; 91: 11–6.
85. Petruccioli E, Scriba TJ, Petrone L, Hatherill M, Cirillo DM, Joosten SA, Ottenhoff TH, Denkinger CM, Goletti D. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. Eur. Respir. J. 2016; 48: 1751–63.
86. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, Fielding K, Wilkinson RJ, Pai M. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect. Dis. 2012; 12: 45–55.
87. Wallis RS, Peppard T. Early biomarkers and regulatory innovation in multidrug-resistant tuberculosis. Clin. Infect. Dis. 2015; 61(Suppl. 3): S160–3.
88. Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Hussey GD et al.; ACS and GC6-74 Cohort Study Groups. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet 2016; 387: 2312–22.
89. Kaforou M, Wright VJ, Levin M. Host RNA signatures for diagnostics: an example from paediatric tuberculosis in Africa. J. Infect. 2014; 69(Suppl. 1): S28–31.
90. Sloot R, Schim van der Loeff MF, van Zwet EW, Haks MC, Keizer ST, Scholing M, Ottenhoff TH, Borgdorff MW, Joosten SA. Biomarkers can identify pulmonary tuberculosis in HIV-infected drug users months prior to clinical diagnosis. EBioMedicine 2014; 2: 172–9.
91. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA et al.; MVA85A 020 Trial Study Team Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013; 381: 1021–8.
92. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ; REMoxTB Consortium. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N. Engl. J. Med. 2014; 371: 1577–87.
93. Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, Van T, Chen RY, Warwick J, Via LE et al. Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure. Nat. Med. 2016; 22: 1094–100.
94. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 2004; 1: 189–95.
95. Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am. J. Respir. Crit. Care Med. 2003; 167: 1348–54.
96. Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am. Rev. Respir. Dis. 1993; 147: 1062–3.
97. Horne DJ, Royce SE, Gooze L, Narita M, Hopewell PC, Nahid P, Steingart KR. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect. Dis. 2010; 10: 387–94.
98. Chengalroyen MD, Beukes GM, Gordhan BG, Streicher EM, Churchyard G, Hafner R, Warren R, Otwombe K, Martinson N, Kana BD. Detection and quantification of differentially culturable tubercle bacteria in sputum from patients with tuberculosis. Am. J. Respir. Crit. Care Med. 2016; 194: 1532–40.
99. Li L, Mahan CS, Palaci M, Horter L, Loeffelholz L, Johnson JL, Dietze R, Debanne SM, Joloba ML, Okwera A et al. Sputum Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to antituberculosis therapy. J. Clin. Microbiol. 2010; 48: 46–51.
100. Desjardin LE, Perkins MD, Wolski K, Haun S, Teixeira L, Chen Y, Johnson JL, Ellner JJ, Dietze R, Bates J et al. Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy. Am. J. Respir. Crit. Care Med. 1999; 160: 203–10.
101. Honeyborne I, McHugh TD, Phillips PP, Bannoo S, Bateson A, Carroll N, Perrin FM, Ronacher K, Wright L, van Helden PD et al. Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment. J. Clin. Microbiol. 2011; 49: 3905–11.
102. Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, Phillips PP, Venter A, Bateson A, Boehme CC et al.; Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics (PanACEA). Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir. Med. 2013; 1: 462–70.
103. Peter JG, Cashmore TJ, Meldau R, Theron G, van Zyl-Smit R, Dheda K. Diagnostic accuracy of induced sputum LAM ELISA for tuberculosis diagnosis in sputum-scarce patients. Int. J. Tuberc. Lung Dis. 2012; 16: 1108–12.
104. Burman WJ. The hunt for the elusive surrogate marker of sterilizing activity in tuberculosis treatment. Am. J. Respir. Crit. Care Med. 2003; 167: 1299–301.
105. Sloan DJ, Mwandumba HC, Garton NJ, Khoo SH, Butterworth AE, Allain TJ, Heyderman RS, Corbett EL, Barer MR, Davies GR. Pharmacodynamic modeling of bacillary elimination rates and detection of bacterial lipid bodies in sputum to predict and understand outcomes in treatment of pulmonary tuberculosis. Clin. Infect. Dis. 2015; 61: 1–8.
106. Ottenhoff TH, Dass RH, Yang N, Zhang MM, Wong HE, Sahiratmadja E, Khor CC, Alisjahbana B, van Crevel R, Marzuki S et al. Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PLoS One 2012; 7: e45839.
107. Honeyborne I, McHugh TD, Kuittinen I, Cichonska A, Evangelopoulos D, Ronacher K, van Helden PD, Gillespie SH, Fernandez-Reyes D, Walzl G et al. Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy. BMC Med. 2016; 14: 68.
108. Cliff JM, Cho JE, Lee JS, Ronacher K, King EC, van Helden P, Walzl G, Dockrell HM. Excessive cytolytic responses predict tuberculosis relapse after apparently successful treatment. J. Infect. Dis. 2016; 213: 485–95.
109. Ameglio F, Casarini M, Capoluongo E, Mattia P, Puglisi G, Giosue S. Post-treatment changes of six cytokines in active pulmonary tuberculosis: differences between patients with stable or increased fibrosis. Int. J. Tuberc. Lung Dis. 2005; 9: 98–104.
110. Su WL, Perng WC, Huang CH, Yang CY, Wu CP, Chen JH. Association of reduced tumor necrosis factor alpha, gamma interferon, and interleukin-1beta (IL-1beta) but increased IL-10 expression with improved chest radiography in patients with pulmonary tuberculosis. Clin. Vaccine Immunol. 2010; 17: 223–31.
111. Wang JY, Chang HC, Liu JL, Shu CC, Lee CH, Wang JT, Lee LN. Expression of toll-like receptor 2 and plasma level of interleukin-10 are associated with outcome in tuberculosis. Eur. J. Clin. Microbiol. Infect. Dis. 2012; 31: 2327–33.
112. Hong JY, Lee HJ, Kim SY, Chung KS, Kim EY, Jung JY, Park MS, Kim YS, Kim SK, Chang J et al. Efficacy of IP-10 as a biomarker for monitoring tuberculosis treatment. J. Infect. 2014; 68: 252–8.
113. Ugarte-Gil CA, Elkington P, Gilman RH, Coronel J, Tezera LB, Bernabe-Ortiz A, Gotuzzo E, Friedland JS, Moore DA. Induced sputum MMP-1, -3 & -8 concentrations during treatment of tuberculosis. PLoS One 2013; 8: e61333.
114. Lee MR, Tsai CJ, Wang WJ, Chuang TY, Yang CM, Chang LY, Lin CK, Wang JY, Shu CC, Lee LN et al. Plasma biomarkers can predict treatment response in tuberculosis patients: a prospective observational study. Medicine (Baltimore). 2015; 94: e1628.
115. Shu CC, Wu MF, Hsu CL, Huang CT, Wang JY, Hsieh SL, Yu CJ, Lee LN, Yang PC. Apoptosis-associated biomarkers in tuberculosis: promising for diagnosis and prognosis prediction. BMC Infect. Dis. 2013; 13: 45.
116. Cirillo DM, Barcellini L, Goletti D. Preliminary data on precision of QuantiFERON-TB Plus performance. Eur. Respir. J. 2016; 48: 955–6.
117. Kamada A, Amishima M. QuantiFERON-TB(R) Gold Plus as a potential tuberculosis treatment monitoring tool. Eur. Respir. J. 2017; 49.
118. De Groote MA, Nahid P, Jarlsberg L, Johnson JL, Weiner M, Muzanyi G, Janjic N, Sterling DG, Ochsner UA. Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment. PLoS One 2013; 8: e61002.
119. Danelishvili L, Shulzhenko N, Chinison JJJ, Babrak L, Hu J, Morgun A, Burrows G, Bermudez LE. Mycobacterium tuberculosis proteome response to antituberculosis compounds reveals metabolic "escape" pathways that prolong bacterial survival. Antimicrob. Agents Chemother. 2017; 61: e00430–17.
120. Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, Scriba TJ, Mahomed H, Hanekom W, Bart PA et al. COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat. Biotechnol. 2015; 33: 610–6.